Prevention of sudden cardiac death with implantable cardioverter- defibrillators in children and adolescents with hypertrophic cardiomyopathy

Journal of the American College of Cardiology

Volumn 61, Issue 14, 2013, Pages 1527-1535

  Maron, Barry J ^a   Spirito, Paolo ^b   Ackerman, Michael J ^c   Casey, Susan A ^a   Semsarian, Christopher ^d   Estes III, N A Mark ^e   Shannon, Kevin M ^f   Ashley, Euan A ^g   Day, Sharlene M ^h   Pacileo, Giuseppe ⁱ   Formisano, Francesco ^b   Devoto, Emmanuela ^b   Anastasakis, Aristidis ^j   Bos, J Martijn ^c   Woo, Anna ^k   Autore, Camillo ^l   Pass, Robert H ^m   Boriani, Giuseppe ⁿ   Garberich, Ross F ^a   Almquist, Adrian K ^a   Russell, Mark W ^h   Boni, Luca ^o   Berger, Stuart ^p   Maron, Martin S ^e   Link, Mark S ^e   more..

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b GALLIERA HOSPITAL   (Italy)

^c MAYO CLINIC   (United States)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e TUFTS MEDICAL CENTER   (United States)

^f UCLA MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ SECOND UNIVERSITY OF NAPLES   (Italy)

^j UNIVERSITY OF ATHENS   (Greece)

^k TORONTO GENERAL HOSPITAL   (Canada)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

ⁿ UNIVERSITY OF BOLOGNA   (Italy)

^o ISTITUTO TOSCANO TUMORI   (Italy)

^p Children's Hospital of Wisconsin   (United States)

more..

Author keywords

cardiomyopathy; children; defibrillators; sudden death; ventricular fibrillation

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; ELECTROGRAPHY; FAINTNESS; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART PACING; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCLE RESECTION; PRESCHOOL CHILD; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SECONDARY PREVENTION; SUDDEN DEATH; TREATMENT RESPONSE;

ADOLESCENT; AGE FACTORS; AUSTRALIA; CANADA; CARDIOMYOPATHY, HYPERTROPHIC; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84875766885     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.01.037     Document Type: Article

References (38)

1. B.J. Maron Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy Circulation 121 2010 445 456
2. P.M. Elliott, J. Poloniecki, S. Dickie Sudden death in hypertrophic cardiomyopathy: identification of high risk patients J Am Coll Cardiol 36 2000 2212 2218
3. B.J. Maron, W.-K. Shen, M.S. Link Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy N Engl J Med 342 2000 365 373
4. B.J. Maron, P. Spirito, W.-K. Shen Implantable cardioverter- defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy JAMA 298 2007 405 412
5. J. Pablo Kaski, M.T. Tomé Esteban, M. Lowe Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy Heart 93 2007 372 374
6. C.I. Berul, G.F. Van Hare, N.J. Kertesz Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients J Am Coll Cardiol 51 2008 1685 1691
7. T. Korte, H. Köditz, M. Niehaus, T. Paul, J. Tebbenjohanns High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator Pacing Clin Electrophysiol 27 2004 924 932
8. A.F. Schinkel, P.A. Vriesendorp, E.J. Sijbrands, L.J. Jordaens, F.J. ten Cate, M. Michels Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis Circ Heart Fail 5 2012 552 559
9. B.J. Maron, W.J. McKenna, G.K. Danielson ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy J Am Coll Cardiol 42 2003 1687 1713
10. B.J. Gersh, B.J. Maron, R.O. Bonow 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy J Am Coll Cardiol 58 2011 e212 e260
11. B.J. Maron, C.E. Seidman, M.J. Ackerman What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy Circ Cardiovasc Genet 2 2009 81 86
12. B.J. Maron, W.C. Roberts, M. Arad Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy JAMA 301 2009 1253 1259
13. P. Spirito, P. Bellone, K.M. Harris, P. Bernabo, P. Bruzzi, B.J. Maron Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy N Engl J Med 342 2000 1778 1785
14. M.D. Pettersen, W. Du, M.E. Skeens, R.A. Humes Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study J Am Soc Echocardiogr 21 2008 922 934
15. B.J. Maron, M.S. Maron Hypertrophic cardiomyopathy Lancet 381 2013 242 255
16. B.J. Maron, M.S. Maron, C. Semsarian Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives J Am Coll Cardiol 60 2012 705 715
17. P. Spirito, C. Autore, C. Rapezzi Syncope and risk of sudden death in hypertrophic cardiomyopathy Circulation 119 2009 1703 1710
18. J.M. Bos, B.J. Maron, M.J. Ackerman Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy Am J Cardiol 106 2010 1481 1486
19. I. Olivotto, B.J. Maron, A. Montereggi, F. Mazzuoli, A. Dolara, F. Cecchi Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy J Am Coll Cardiol 33 1999 2044 2051
20. K.M. Harris, P. Spirito, M.S. Maron Prevalence, clinical profile and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy Circulation 114 2006 216 225
21. R.G. Hauser, B.J. Maron Lessons from the failure and recall of an implantable cardioverter defibrillator Circulation 112 2005 2040 2042
22. B.J. Maron, P. Spirito Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy J Cardiovasc Electrophysiol 19 2008 1118 1126
23. I. Jayatilleke, A. Doolan, J. Ingles Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy Am J Cardiol 93 2004 1192 1194
24. A. Woo, D. Monakier, L. Harris Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy Heart 93 2007 1044 1045
25. D.A. Begley, S.A. Mohiddin, D. Tripodi, J.B. Winkler, L. Fananapazir Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy Pacing Clin Electrophysiol 26 2003 1887 1896
26. C. Prinz, J. Vogt, T. Bitter Incidence of adequate ICD interventions in patients with hypertrophic cardiomyopathy supposed to be at high risk for sudden cardiac death Acta Cardiol 65 2010 521 525
27. B.J. Maron, I. Olivotto, P. Spirito Epidemiology of hypertrophic cardiomyopathy-related death Revisited in a large non-referral-based patient population Circulation 102 2000 858 864
28. L. Monserrat, P.M. Elliott, J.R. Gimeno, S. Sharma, M. Penas-Lado, W.J. McKenna Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients J Am Coll Cardiol 42 2003 873 879
29. B.J. Maron, T.S. Haas, K.M. Shannon, A.K. Almquist, J.S. Hodges Long-term survival after cardiac arrest in hypertrophic cardiomyopathy Heart Rhythm 6 2009 993 997
30. T.B. Morrison, P.A. Friedman, L.M. Kallinen Impact of implanted recalled sprint Fidelis lead on patient mortality J Am Coll Cardiol 58 2011 278 283
31. B.J. Maron, D.P. Zipes 36th Bethesda Conference: eligibility recommendations for competitive athletes with cardiovascular abnormalities J Am Coll Cardiol 45 2005 1312 1375
32. J.W.E. Jarman, K. Lascelles, T. Wong, V. Markides, J.R. Clague, J. Till Clinical experience of entirely subcutaneous implantable cardioverter- defibrillators in children and adults: cause for caution Eur Heart J 33 2012 1351 1359
33. R.G. Hauser The subcutaneous implantable cardioverter-defibrillator Should patients want one? J Am Coll Cardiol 61 2013 20 22
34. G. Boriani, B.J. Maron, W.-K. Shen, P. Spirito Prevention of sudden death in hypertrophic cardiomyopathy But which defibrillator for which patient? Circulation 110 2004 e438 e442
35. R. Tung, P. Zimetbaum, M.E. Josephson A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death J Am Coll Cardiol 52 2008 1111 1121
36. A.A. Alsheikh-Ali, M.S. Link, C. Semsarian et al. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients Heart Rhythm 10 2013 214 218
37. K.A. Ellenbogen, J.H. Levine, R.D. Berger Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 113 2006 776 782
38. S.J. Connolly Use and misuse of surrogate outcomes in arrhythmia trials Circulation 113 2006 764 766